von Suesskind-Schwendi, M. and Valenti, Verena and Haneya, Assad and Puehler, T. and Bewig, B. and Schmid, C. and Hirt, S. W. and Lehle, K. (2013) Synergism of imatinib mesylate and everolimus in attenuation of bronchiolitis obliterans after rat LTX. HISTOLOGY AND HISTOPATHOLOGY, 28 (10). pp. 1273-1284. ISSN 0213-3911, 1699-5848
Full text not available from this repository. (Request a copy)Abstract
Bronchiolitis obliterans (BO) is a progressive and fatal disease after lung transplantation (LTX). Dysregulated growth factor-induced proliferation of myofibroblasts seems to be responsible for the development of BO. The aim was to confirm the efficacy of both inhibitors of receptor tyrosine kinases (RTKI) and of mammalian target of rapamycin (mTORI) after rat LTX. We used a rat model of left lung allotransplantation (F344-to-WKY) to evaluate the effect of imatinib (RTKI; 20 mg/kg/day; postoperative day (POD) 0-100) alone or in combination with everolimus (mTORI; 2.5 mg/kg/day; POD 14-100). Non-treated animals were the reference. In non-treated rats, acute rejection (AR) peaked between POD 20 and 30 (19/19) and ended in chronic rejection (CR) on POD 60/100 (12/12). Imatinib alone did not prevent AR (6/6), but attenuated the degree of degenerated bronchioles on POD 30 (non-treated, 57%; imatinib, 4%), and increased the allografts free of CR on POD 60/100 (3/12). A combination of imatinib and everolimus significantly reduced AR, attenuated fibrotic degenerated bronchioles (5%) and vessels (non-treated, 24%; combination therapy, 11%) on POD 30, and reduced fibrotic degenerated vessels (non-treated, 97%; combination therapy, 43%) and bronchioles (non-treated, 88%; combination therapy, 34%) on POD 60/100. Fifty percent of the animals were completely free of BO and vasculopathy. In conclusion, co-application of RTKI and mTORI attenuated the development of BO and vasculopathy. Thus, imatinib might be an interesting therapeutic approach after LTX.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CHRONIC ALLOGRAFT-REJECTION; CHRONIC MYELOID-LEUKEMIA; LUNG TRANSPLANTATION; ALPHA(1)-ACID GLYCOPROTEIN; ALPHA-1-ACID GLYCOPROTEIN; EPITHELIAL-CELLS; GROWTH-FACTOR; PHARMACOKINETICS; CYCLOSPORINE; COMBINATION; Lung transplantation; Rat; mTOR-inhibitor; RTK-inhibitor; Chronic rejection |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Herz-, Thorax- und herznahe Gefäßchirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Mar 2020 12:56 |
| Last Modified: | 30 Mar 2020 12:56 |
| URI: | https://pred.uni-regensburg.de/id/eprint/15984 |
Actions (login required)
 |
View Item |
